Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Operating Expenses: 2022-2025

Historic Operating Expenses for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to -$929,197.

  • Addex Therapeutics' Operating Expenses rose 17.18% to -$929,197 in Q2 2025 from the same period last year, while for Jun 2025 it was $5.8 million, marking a year-over-year increase of 37.27%. This contributed to the annual value of $3.6 million for FY2024, which is 16.29% down from last year.
  • Addex Therapeutics' Operating Expenses amounted to -$929,197 in Q2 2025, which was down 223.34% from $753,346 recorded in Q1 2025.
  • In the past 5 years, Addex Therapeutics' Operating Expenses ranged from a high of $7.7 million in Q4 2023 and a low of -$7.6 million during Q4 2022.
  • In the last 3 years, Addex Therapeutics' Operating Expenses had a median value of -$934,744 in 2025 and averaged $547,127.
  • As far as peak fluctuations go, Addex Therapeutics' Operating Expenses skyrocketed by 201.71% in 2023, and later fell by 24.65% in 2024.
  • Addex Therapeutics' Operating Expenses (Quarterly) stood at -$7.6 million in 2022, then spiked by 201.71% to $7.7 million in 2023, then dropped by 12.86% to $6.7 million in 2024, then increased by 17.18% to -$929,197 in 2025.
  • Its Operating Expenses stands at -$929,197 for Q2 2025, versus $753,346 for Q1 2025 and $6.7 million for Q4 2024.